Skip to main content

THC clinical trials at University of California Health

5 in progress, 2 open to eligible people

Showing trials for
  • Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

    open to eligible people ages 21-70

    This study has the potential to contribute to a more complete understanding of the independent and combined effects of cannabis use and HIV on the brain and on inflammation. Such knowledge may inform future strategies for treating brain disease and inflammation. Participants will be randomly assigned to one of two groups, both of which will receive the same treatment in a different order over a period of about 6 weeks. The visits include physical examinations, blood tests, and other procedures designed to monitor subject safety and measure the effects of the study drug.

    at UCSD

  • THC Crossover Study

    open to eligible people ages 21 years and up

    This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from smoking and vaping dry herb cannabis. This study will also examine the differences in toxicant exposure and cardiovascular disease risk between smoking cannabis and smoking tobacco cigarettes.

    at UCSF

  • Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults

    Sorry, not yet accepting patients

    The goal of this interventional study is to determine the impact of high potency THC product use on cognitive function of young adults aged 21-25. The main question it aims to answer is: will cannabis users who switch to less potent THC products demonstrate improved cognitive function compared to baseline? Other questions this study aims to answer include: - Can researchers accurately assess THC consumption among frequent cannabis users? - Can researchers effectively incentivize cannabis users to use less potent THC products? - Do genetic variations in THC metabolism impact urinary THC excretion? - Do genetic variations in THC metabolism impact cognitive performance in cannabis users? - Are quantitative urinary THC values predictive of cognitive impairment? - How can researchers use research findings to inform harm reduction practices for people who use cannabis? Participants will submit blood and urine samples and be incentivized to use less potent THC products.

    at UCSF

  • Inhaled Cannabis for Acute Migraine Treatment

    Sorry, accepting new patients by invitation only

    This pilot crossover study will evaluate 3 different potencies of inhaled cannabis (2.5%, 5%, and 10%) and inhaled placebo cannabis for the acute treatment of migraine.

    at UCSD

  • Clinical Pharmacology of Marijuana-Tobacco Co-administration

    Sorry, not yet accepting patients

    This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.

    at UCSF

Our lead scientists for THC research studies include .

Last updated: